VRTX
Vertex PharmaceuticalsPrevious close
558.88
Change
+18.88 / +3.50%
P/E (TTM) ?
30.6
Market Cap
$133B
1M
+6.90%
S&P 500 −0.91% over same period
Volume / Avg Volume
3.0M / 1.3M
2.38× average
Latest earnings analysisFY2026 Q2Reported 2026-08-03
Vertex Q2 2026: revenue up 12% to $3.33 billion, guidance raised
Vertex's second quarter was a top-line story: revenue rose 12% to $3.33 billion, management nudged full-year guidance to $13.1 billion to $13.2 billion, and non-GAAP EPS of $4.73 landed just under the $4.83 consensus. Read the quarter as cystic fibrosis still paying the bills, ALYFTREK taking over that franchise, and CASGEVY and JOURNAVX only starting to matter. Every figure below comes from the company's own release and balance sheet.
Read the full analysis →Revenue$3.33BYoY +12.50%
EPS (non-GAAP)$4.73Missest. $4.83
Next-quarter revenue guidance$13.15B ±0.38%YoY +294.40%
Next-day move+1.70%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-08-03 | $3.3B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-05-04 | $3.0B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-12 | $12.0B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-11-03 | $3.1B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-08-04 | $3.0B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-05-05 | $2.8B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 68 of its 5-year rangeMid-range
5-year range 26.5 – 32.5 · Median 29.6
Last 4 quarters: $2.0B in buybacks + $0 in dividends, 1.51% of market cap combined
P/E (TTM)
30.6
P/B
6.7
P/S
10.7
PEG
2.10
Earnings Reaction
Over the last 6 reports, the stock moved ±6.7% on average on the first trading day after, rising 2 times
Most recent +1.70%
Volatility & Correlation
1-year beta 0.45 · Correlation with S&P 500 0.20Low beta
Annualized volatility 29% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 3.33 | +12.5% | 85.3% | 1.10 | 4.31 |
| FY2026 Q1 | 2.99 | +7.8% | 86.8% | 1.03 | 4.02 |
| FY2025 Q4 | 3.19 | +9.5% | 85.4% | 1.19 | 4.64 |
| FY2025 Q3 | 3.08 | +11.0% | 86.5% | 1.08 | 4.20 |
| FY2025 Q2 | 2.96 | +12.1% | 86.3% | 1.03 | 3.99 |
| FY2025 Q1 | 2.77 | +3.0% | 86.9% | 0.65 | 2.49 |
| FY2024 Q4 | 2.91 | +15.7% | 85.5% | 0.91 | 3.62 |
| FY2024 Q3 | 2.77 | +11.6% | 85.8% | 1.05 | 4.01 |
| FY2024 Q2 | 2.65 | +6.1% | 85.9% | -3.59 | -13.92 |
| FY2024 Q1 | 2.69 | +13.3% | 87.3% | 1.10 | 4.21 |
| FY2023 Q4 | 2.52 | +9.3% | 85.4% | 0.97 | 3.71 |
| FY2023 Q3 | 2.48 | +6.4% | 87.2% | 1.04 | 3.97 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| VRTX | 30.6 | +12.5% | 85.3% | +6.90% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |